What are the standard first-line treatment options for Stomach Cancer

Standard First-Line Treatment Options for Stomach Cancer

The approach to treating stomach cancer depends on several key factors: whether the cancer can be surgically removed (resectable), how advanced it is, and your overall health status. Let me walk you through the standard options.

THE CLINICAL DECISION-MAKING FRAMEWORK

According to NCCN Guidelines for Gastric Cancer (Version 3.2025), doctors evaluate stomach cancer using a multidisciplinary approach—meaning your surgical team, medical oncologists, and radiation specialists work together to determine the best path forward.

The first critical step is staging to understand how far the cancer has spread:

• Early-stage disease (confined to the stomach lining): T1a or T1b tumors
• Locally advanced disease (deeper into stomach wall or nearby lymph nodes): T2-T4 tumors
• Metastatic disease (spread to distant organs): Stage IV

---

STANDARD FIRST-LINE TREATMENT OPTIONS

For Potentially Resectable Disease (Can Be Surgically Removed)

Perioperative Systemic Therapy (Category 1 - Highest Priority)

This is the preferred approach for medically fit patients. "Perioperative" means chemotherapy given before AND after surgery:

• Neoadjuvant chemotherapy (before surgery): Shrinks the tumor to make surgery safer and more effective
• Surgery: Gastrectomy (partial or total stomach removal) with lymph node dissection
• Adjuvant chemotherapy (after surgery): Eliminates remaining cancer cells

According to NCCN Guidelines, this combined approach is a Category 1 recommendation, meaning it's the most strongly supported by evidence.

Special consideration for MSI-H/dMMR tumors: If your tumor has high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)—biomarkers your doctor should test for—immunotherapy (immune checkpoint inhibitors) may be considered as part of perioperative treatment.

---

For Surgically Unresectable Disease (Cannot Be Removed)

Systemic Chemotherapy or Chemoradiation

If surgery isn't possible due to tumor extent or your medical condition:

• Chemotherapy alone (preferred for most patients)
• Chemoradiation (chemotherapy + radiation therapy combined)

These aim to control the cancer and manage symptoms.

---

For Early-Stage Disease (T1a or T1b)

Endoscopic Resection (ER)

For very early cancers confined to the stomach lining:

• Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)
• These are minimally invasive procedures done through the mouth
• Can be both diagnostic AND therapeutic
• Followed by endoscopic surveillance (regular monitoring)

---

IMPORTANT BIOMARKER TESTING

Before starting treatment, NCCN Guidelines recommend universal testing for:

1. MSI (Microsatellite Instability) or MMR (Mismatch Repair) status - determines if immunotherapy may help
2. PD-L1 expression - helps predict response to immunotherapy
3. HER2 status - if advanced/metastatic disease (determines if targeted therapy applies)
4. CLDN18.2 - if advanced/metastatic disease (emerging biomarker for targeted therapy)
5. Next-Generation Sequencing (NGS) - should be considered to identify other actionable mutations

These tests help personalize your treatment plan.

---

WHAT THIS MEANS FOR YOUR SITUATION

The "standard" first-line approach for most patients with resectable stomach cancer is:

✅ Chemotherapy → Surgery → More Chemotherapy

However, YOUR specific treatment will depend on:

• Exact stage and location of your tumor
• Results of biomarker testing
• Your overall health and ability to tolerate surgery
• Your preferences and goals of care

---

QUESTIONS TO ASK YOUR ONCOLOGY TEAM

1. What is the stage and exact location of my cancer? (This determines which treatment pathway applies to me)
2. What biomarker tests have been done, and what do the results show? (Especially MSI/MMR and HER2 status)
3. Am I a candidate for surgery, and if so, when would it be scheduled?
4. What chemotherapy regimen is recommended for me, and what are the expected side effects?
5. If my tumor is MSI-H or dMMR, should immunotherapy be considered as part of my treatment?
6. What is the goal of treatment—cure, control, or symptom management? (This helps align expectations)
7. Are there clinical trials available for my specific stage and biomarker profile?

---

IMPORTANT CONTEXT

According to NCCN Guidelines, treatment decisions should involve a multidisciplinary team consultation. This means your care should include input from:

• Surgical oncologist
• Medical oncologist
• Radiation oncologist (if applicable)
• Gastroenterologist
• Pathologist (for biomarker interpretation)

This collaborative approach ensures you receive the most comprehensive, personalized care.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.